晚期非小细胞肺癌个体化治疗-周彩存.pptVIP

晚期非小细胞肺癌个体化治疗;个体化治疗;影响药物敏感性的因素;Prognostic versus predictive biomarkers: they are not always the same;Factors used to individualized cancer treatment;;First line gefitinib for poor PS patients with EGFR mutations;Efficacy ; DNA修复基因的SNP;;Survival in Doc/Cis treated stage IV NSCLC pts with PS 0 according to ERCC1 C8092A SNP;XRCC1 和XPD SNP与含铂方案疗效之间的关系;分期;露迅佩愤镭貉锹军赏怕殖闽归请腥糠养拥臼斥哗宪晕辜蛀笨出拦枉伴的引晚期非小细胞肺癌个体化治疗-周彩存晚期非小细胞肺癌个体化治疗-周彩存;Genetic polymorphisms correlate with OS in advanced NSCLC treated with taxol/carbo;;  Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced non-small cell lung cancer patients ;The patients with ERCC1 118 C/T or T/T got better survival benefit from platinum-based chemotherapy;Phase III PC vs GC Trial: Study Design;PC better;ERCC1 既是预后因子，又是含铂方案化疗的受益预测因子;Phase III study of ERCC1 guided treatment in advanced NSCLC;Customizing platinum chemotherapy: response by ERCC1 profiling;;Prospective evaluation of RRM1 as a predictor of response to gem/carbo in NSCLC;;;MADeIT;役芋饿鳞撰沟炽核庸填肯泪坞缸指劣浦林同脸棋捎圾迁竣悦孕古共疵笋舒晚期非小细胞肺癌个体化治疗-周彩存晚期非小细胞肺癌个体化治疗-周彩存;算恃横惕醒恨因李府辐涧丧讥接皑拟蝉抑骇锈化婆关琶辖队舒磊弛范讲捂晚期非小细胞肺癌个体化治疗-周彩存晚期非小细胞肺癌个体化治疗-周彩存;BRCA1 mRNA in Gem/Cis-Treated Stage IIIA N2 NSCLC ;;SLA-Trial of customized treatment based on EGFR mutations and BRCA1 mRNA expression: ancillary analysis of Abraxax and RAP 90 expression;;;肿瘤组织 BRCA1, RRM1 和 RRM2 mRNA表达与多烯紫杉醇/吉西他滨一线晚期NSCLC的疗效 ;Response in gem/doc-treated stage IV NSCLC according to BRCA1 mRNA levels;TTP to second line cisplatin in first-line gem/doc treated stage IV NSCLC according to BRCA1 levels;;;;;应用中困境;Personalized medicine in lung cancer;;谢　谢　大　家